StackTerminal.Health

Coenzyme Q10

Endogenous antioxidant and mitochondrial cofactor with evidence in heart failure and statin-induced myopathy.

cardiolongevitymitochondrial
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
100 mg
Max dose
300 mg
Rounding
50 mg

Stacks containing Coenzyme Q10

Public community stacks that include this ingredient.

Explore all stacks →
metaboliclongevityhealthspan

Targets glucose and lipid markers for long-term metabolic health.

Berberine
10000mg
Coenzyme Q10
200mg
New
View
longevity

Targets cardiometabolic markers associated with long-term health.

Omega-3 (EPA/DHA)
2000mg
Coenzyme Q10
200mg
New
View
longevity

Targets glucose and lipid markers for long-term metabolic health.

Berberine
1000mg
Coenzyme Q10
200mg
New
View
Evidence
2 records
Morbidity and mortality in chronic heart failure
Adults with moderate-to-severe chronic heart failureRandomized double-blind placebo-controlled trial (Q-SYMBIO)
Moderate

CoQ10 100 mg three times daily over 2 years reduced major adverse cardiovascular events (15% vs 26% placebo) and all-cause mortality (10% vs 18% placebo; RR 0.58, 95% CI 0.35–0.95) in addition to standard therapy.

Dose: 300 mg Duration: 2 years
Landmark RCT; conducted in patients on background heart failure therapy.
Statin-associated muscle symptoms (myalgia, weakness, cramps)
Adults experiencing statin-induced myopathySystematic review and meta-analysis of RCTs
Low

CoQ10 supplementation significantly improved statin-associated muscle pain (WMD −1.60), weakness (WMD −2.28), cramps (WMD −1.78), and tiredness (WMD −1.75) across 12 RCTs (n=575), though plasma creatine kinase was not significantly reduced.

Dose:
Symptom improvement without biochemical marker change; overall evidence quality is low due to small trial sizes.
Forms
Ubiquinol or ubiquinone
Ubiquinol may have better absorption in older adults.